47 related articles for article (PubMed ID: 16616004)
21. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
Durdagi S; Duff HJ; Noskov SY
J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
[TBL] [Abstract][Full Text] [Related]
22. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
Aronov AM
J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
[TBL] [Abstract][Full Text] [Related]
23. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
[TBL] [Abstract][Full Text] [Related]
24. Computer simulations of structure-activity relationships for HERG channel blockers.
Boukharta L; Keränen H; Stary-Weinzinger A; Wallin G; de Groot BL; Aqvist J
Biochemistry; 2011 Jul; 50(27):6146-56. PubMed ID: 21657256
[TBL] [Abstract][Full Text] [Related]
25. Blockade of HERG K+ channel by an antihistamine drug brompheniramine requires the channel binding within the S6 residue Y652 and F656.
Park SJ; Kim KS; Kim EJ
J Appl Toxicol; 2008 Mar; 28(2):104-11. PubMed ID: 17516459
[TBL] [Abstract][Full Text] [Related]
26. A novel hypothesis for the binding mode of HERG channel blockers.
Choe H; Nah KH; Lee SN; Lee HS; Lee HS; Jo SH; Leem CH; Jang YJ
Biochem Biophys Res Commun; 2006 May; 344(1):72-8. PubMed ID: 16616004
[TBL] [Abstract][Full Text] [Related]
27. The interactions between hERG potassium channel and blockers.
Du L; Li M; You Q
Curr Top Med Chem; 2009; 9(4):330-8. PubMed ID: 19442204
[TBL] [Abstract][Full Text] [Related]
28. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
29. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Narayana Moorthy NS; Ramos MJ; Fernandes PA
Curr Drug Targets; 2013 Jan; 14(1):102-13. PubMed ID: 23061466
[TBL] [Abstract][Full Text] [Related]
30. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology.
Taboureau O; Jørgensen FS
Comb Chem High Throughput Screen; 2011 Jun; 14(5):375-87. PubMed ID: 21470179
[TBL] [Abstract][Full Text] [Related]
31. Development of Safe Drugs: The hERG Challenge.
Kalyaanamoorthy S; Barakat KH
Med Res Rev; 2018 Mar; 38(2):525-555. PubMed ID: 28467598
[TBL] [Abstract][Full Text] [Related]
32. Computational investigations of hERG channel blockers: New insights and current predictive models.
Villoutreix BO; Taboureau O
Adv Drug Deliv Rev; 2015 Jun; 86():72-82. PubMed ID: 25770776
[TBL] [Abstract][Full Text] [Related]
33. In silico prediction of hERG inhibition.
Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
[TBL] [Abstract][Full Text] [Related]
34. Predictive in silico modeling for hERG channel blockers.
Aronov AM
Drug Discov Today; 2005 Jan; 10(2):149-55. PubMed ID: 15718164
[TBL] [Abstract][Full Text] [Related]
35. Recent developments in computational prediction of HERG blockage.
Wang S; Li Y; Xu L; Li D; Hou T
Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
[TBL] [Abstract][Full Text] [Related]
36. Predictive models for HERG channel blockers: ligand-based and structure-based approaches.
Thai KM; Ecker GF
Curr Med Chem; 2007; 14(28):3003-26. PubMed ID: 18220737
[TBL] [Abstract][Full Text] [Related]
37. Ligand structural aspects of hERG channel blockade.
Aronov AM
Curr Top Med Chem; 2008; 8(13):1113-27. PubMed ID: 18782007
[TBL] [Abstract][Full Text] [Related]
38. Implications of Dynamic Occupancy, Binding Kinetics, and Channel Gating Kinetics for hERG Blocker Safety Assessment and Mitigation.
Pearlstein RA; MacCannell KA; Erdemli G; Yeola S; Helmlinger G; Hu QY; Farid R; Egan W; Whitebread S; Springer C; Beck J; Wang HR; Maciejewski M; Urban L; Duca JS
Curr Top Med Chem; 2016; 16(16):1792-818. PubMed ID: 26975508
[TBL] [Abstract][Full Text] [Related]
39. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?
Ritchie TJ; Macdonald SJ
Drug Discov Today; 2009 Nov; 14(21-22):1011-20. PubMed ID: 19729075
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
